2023 Volume 12 Issue 2 Pages 94-102
Hematopoietic stem cell transplantation for malignant lymphoma (HSCT) is performed as consolidation therapy after induction therapy for selected disease types with high risk of relapse or that for relapsed/refractory cases. Regardless of the type or timing of treatment, HSCT should be performed in chemotherapy-sensitive cases; it has little prognostic value in chemotherapy-resistant patients. Polatuzumab vedotin for diffuse large B-cell lymphoma (DLBCL) and brentuximab vedotin for Hodgkin lymphoma and peripheral T-cell lymphoma are now part of first-line therapy for each disease type. CAR-T cell therapy has also been introduced for relapsed/refractory cases of DLBCL. The position of HSCT for malignant lymphoma continues to change with the development of new therapies, and the indications for HSCT need to be constantly reevaluated.
